

ERRATUM

## Erratum to: Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

Eiji Oki, MD, PhD, FACS<sup>1</sup>, Yasunori Emi, MD, PhD<sup>2</sup>, Yuji Miyamoto, MD, PhD<sup>3</sup>, Akira Kabashima, MD, PhD<sup>4</sup>, Hidefumi Higashi, MD, PhD<sup>5</sup>, Yutaka Ogata, MD, PhD<sup>6</sup>, Masahiko Ikebe, MD, PhD<sup>7</sup>, Hiroshi Saeki, MD, PhD, FACS<sup>1</sup>, Shoji Tokunaga, PhD<sup>8</sup>, Ken Shirabe, MD, PhD, FACS<sup>1</sup>, Toru Beppu, MD, PhD<sup>3</sup>, Shinji Uchida, MD, PhD<sup>6</sup>, Mitsuhisa Takatsuki, MD, PhD<sup>9</sup>, Masahiko Sakoda, MD, PhD<sup>10</sup>, Susumu Eguchi, MD, PhD, FACS<sup>9</sup>, Yoshito Akagi, MD, PhD<sup>11</sup>, Yoshihiro Kakeji, MD, PhD, FACS<sup>12</sup>, Hideo Baba, MD, PhD, FACS<sup>3</sup>, Shoji Natsugoe, MD, PhD<sup>10</sup>, Yoshihiko Maehara, MD, PhD, FACS<sup>1</sup> and Kyushu Study Group of Clinical Cancer (KSCC)

<sup>1</sup>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan; <sup>2</sup>Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan; <sup>3</sup>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; <sup>4</sup>Department of Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; <sup>5</sup>Department of Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan; <sup>6</sup>Department of Surgery, Kurume University Medical Center, Kurume, Japan; <sup>7</sup>Department of Gastroenterological Surgery, Beppu Medical Center, Beppu, Japan; <sup>8</sup>Medical Information Center, Kyushu University Hospital, Fukuoka, Japan; <sup>9</sup>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; <sup>10</sup>Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; <sup>11</sup>Department of Surgery, Kurume University School of Medicine, Kurume, Japan; <sup>12</sup>Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan

### ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-015-4771-1

In first sentence of the Protocol Treatment section on the second page of the original article there is an error in the oxaliplatin dosage. The corrected sentence is as follows: In principle, 4–6 cycles of preoperative chemotherapy—SOX: S-1 is orally administrated at a dose corresponding to the

body surface area (BSA) (40 mg with BSA < 1.25 m<sup>2</sup>; 50 mg with BSA 1.25–1.50 m<sup>2</sup>; 60 mg with BSA > 1.50 m<sup>2</sup>) twice daily after meals for 14 consecutive days, oxaliplatin (130 mg/m<sup>2</sup>) day 1 every 3 weeks, plus cetuximab (400 mg/m<sup>2</sup> as the initial dose) followed by 250 mg/m<sup>2</sup>/week—was administered within 2 weeks after enrollment.

---

The online version of the original article can be found under doi:[10.1245/s10434-015-4771-1](https://doi.org/10.1245/s10434-015-4771-1).

---

© Society of Surgical Oncology 2015

Published Online: 21 Sep 2015

E. Oki, MD, PhD, FACS

e-mail: [okieiji@surg2.med.kyushu-u.ac.jp](mailto:okieiji@surg2.med.kyushu-u.ac.jp)